This is a real-world, pre-post observational study from an ambulatory endocrinology practice
which will determine the effectiveness and safety of the addition of glucagon-like
peptide-1(GLP-1) agonist therapy (weekly exenatide {Bydureon} or daily liraglutide
{Victoza}), added to the regimens of T2DM patients who have already received a minimum of one
year of basal insulin therapy. Specifically, the investigators hypothesize that GLP-1 agonist
therapy added to basal insulin therapy will result in statistically significant improved
glycemic control and weight loss, with no higher risk of hypoglycemia compared to baseline.